the aid library

LIST OPTIONS

Filter

1244

Sort by:

Direction:

Download (2164)

View PDF (6516)

WHO Model Formulary for Children
recommended

World Health Organization WHO (2010) C_WHO

WHO Model Formulary for children based on the Second Model List of Essential Medicines for Children 2009. In 2007, the World Health Assembly passed a Resolution titled ‘Better Medicines for Children’. This resolution recognized the need for research and development into medicines for children,... more

Download (706)

View PDF (1502)

Guidelines on hepatitis B and C testing
recommended

World Health Organization (WHO) (2017) C_WHO

Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to recei... more

Download (627)

View PDF (3063)

Guidelines - European AIDS Clinical Society (EACS)

European AIDS Clinical Society (EACS) European AIDS Clinical Society (EACS) (2020) C2

Version 10.1_5 October 2020 These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website. The 2019 version of the Guidelines introduces a new drug-drug interaction panel and now consists of six main sections, including a general overview ... more

Download (1505)

View PDF (2413)

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
recommended

World Health Organization (2015) C_WHO

The recommendations in these guidelines promote the use of simple, non-invasive diagnostic tests to assess the stage of liver disease and eligibility for treatment; prioritize treatment for those with most advanced liver disease and at greatest risk of mortality; and recommend the preferred use of n... more

Download (172)

View PDF (1496)

Paradise Lost: The Neurobiological and Clinical Consequences of Child Abuse and Neglect

Charles B. Nemeroff Neuron Review (2016) CC

This Review summarizes many of the persistent biological alterations associated with childhood maltreatment including changes in neuroendocrine and neurotransmitter systems and pro-inflammatory cytokines in addition to specific alterations in brain areas associated with mood regulation. Finally, I d... more

Download (1190)

View PDF (1328)

Medicinal products under development for the treatment of Ebola

European Medicines Agency EMA (2014)

Interim Assessement Report The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infecte... more

Download (1228)

View PDF (1477)

Nutrition Topic Guide

Jessica Meeker, Stephen Thompson, Inka Barnett The Health & Education Advice & Resource Team (HEART) (2013)

This Topic Guide has been compiled to provide an overview of undernutrition in the context of development. The focus of the Guide is on undernutrition, defined as the outcome of insufficient (quantity and quality) of food intake (hunger) and repeated infectious diseases. Undernutrition includes bein... more

Download (241)

View PDF (180)

Guidelines for the use of antibiotics in production animals: Cattle, pigs, sheep and goats

The Swedish Veterinary Association SVS (2017) C2

In 1998 the Swedish Veterinary Association decided to adopt a general policy for the use of antibiotics in animals. Since then specifi c policies for the use of antibiotics in dogs and cats have been adopted and in 2011 Guidelines for the use of Antibiotics in Production animals – Cattle and Pigs,... more

Download (122)

View PDF (716)

Standard Treatment Guidelines and Essential Medicines List of Common Medical Conditions

Government of the Kingdom of Swaziland Ministry of Health (2012) C2

The product of all this work is the Standard Treatment Guideline and Essential Medicines List of Common Medical Conditions in the Kingdom of Swaziland. These systematically developed statements are designed to assist practitioners in making decisions about appropriate treatment for specific clinical... more

Download (84)

View PDF (653)

Q&A: Antibiotic resistance: where does it come from and what can we do about it?

Wright G.D. BMC Biology (2010) C2

Historically, the discovery of the sulfa drugs in the 1930s and the subsequent development of penicillin during World War II ushered in a new era in the treatment of infectious diseases. Infections that were common causes of death and disease in the pre-... more

Download (105)

View PDF (147)

Nutritional interventions update: vitamin D supplements during pregnancy

World Health Organization WHO (2020) C_WHO

The World Health Organization’s comprehensive antenatal care (ANC) guideline WHO recommendations on antenatal care for a positive pregnancy experience was first published in 2016 with the objective of improving the quality of routine health care that all women and adolescent girls receive during p... more

Download (67)

View PDF (119)

Реагирование на неинфекционные заболевания во время пандемии COVID-19 и после ее завершения

Всемирная Организация Здравоохранения ВОЗ (2020) C_WHO

В настоящем документе представлен первоначальный обзор поступающей информации (по состоянию на 2 июля 2020 г.) о взаимосвязи между COVID-19, НИЗ и факторами риска НИЗ. Ре... more

Download (145)

View PDF (185)

Mapping the health system response to childhood obesity in the WHO European Region. An overview and country perspectives (2019)

World Health Organization WHO, Regional Office of Europe (2019) C_WHO

Childhood obesity is a major public health problem globally, which could undermine progress towards achieving the Sustainable Development Goals. Prevention is recognized as the most efficient means of curbing the epidemic; however, given the scale of the problem and the many children who need profes... more

Download (83)

View PDF (134)

National Comprehensive Covid19 Management Handbook First Edition 2020

Ministry of Health, Federal Democratic Republic of Ethiopia Ministry of Health, Federal Democratic Republic of Ethiopia (2020) C1

Cognizant of the need for standardization of the response for COVID-19, the Federal Ministry of Health prepared this national guideline in an effort to contain the epidemic before it overwhelms the health care facilities. This national guideline is expected to guide policy makers and h... more

Download (168)

View PDF (225)

Health of People, Health of Planet and Our Responsibility

Al Delaimy W., Ramanathan V., Sanchez Sorondo M. et al. (2020) CC

This open access book not only describes the challenges of climate disruption, but also presents solutions. The challenges described include air pollution, climate change, extreme weather, and related health impacts that range from heat stress, vector-borne diseases, food and water insecurity and ch... more

Download (119)

View PDF (160)

COVID-19 in Latin America and the caribbean region: Symptoms and morbidities in the epidemiology of infection

Anaya-Covarrubias, J.Y.; et al. (2022) C1

Curr Opin Pharmacol . 2022 Apr;63:102203.doi: 10.1016/j.coph.2022.102203. Epub 2022 Feb 11. The COVID-19 pandemic has widespread economic and social effects on Latin America (LA) and the Caribbean (CA). This region, which has a high prevalence of chronic diseases, has been one of the most affected... more

Download (238)

View PDF (164)

Water, Sanitation and Hygiene and Infection Prevention and Control in Cholera Treatment Structures

UN Children's Fund UNICEF Global Task Force on Cholera (2019) C_UNICEF

Technical Note: Cholera treatment facilities provide inpatient care for cholera patients during outbreaks. Proper case management and isolation of cholera patients is essential to prevent deaths and help control the spread of the disease. Traditionally, these structures have been referred to as ch... more

Download (125)

View PDF (170)

WHO interim guidelines for the treatment of gambiense human African trypanosomiasis

World Health Organization WHO (2019) C_WHO

This document focuses on the management of patients affected by gambiense HAT and constitutes an update to the WHO therapeutic guidance issued in 2013. The main changes in recommendations concern the criteria and methods for deciding the treatment among the new set of therapeutic options and the pa... more

Download (548)

View PDF (240)

WHO Guidelines for Malaria- 14 March 2023

World Health Organisation (WHO) (2023) C_WHO

The conditionality of this recommendation is largely driven by the current higher unit cost of pyrethroid-PBO ITNs compared to pyrethroid-only LLINs and therefore the uncertainty of their cost-effectiveness. Furthermore, as PBO is less wash-resistant than pyrethroids, its bioavailability declines ... more

Download (245)

View PDF (330)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

WHO Model Formulary for Children recommended

Guidelines on hepatitis B and C testing recommended

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection recommended

WHO Model Formulary for Children
recommended

Guidelines on hepatitis B and C testing
recommended

Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
recommended